Ixempra Articles

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15 January 2013

FDA grants full approval to B-MS' Sprycel

27 May 2009

B-MS extends Otsuka Abilify deal for $400M upfront; accords for Sprycell and Exempra

6 April 2009

B-MS withdraws Ixempra MAA

30 March 2009

B-MS' Ixempra increases PFS in triple negative BC

22 December 2008

CHMP denies B-MS and Santhera drugs

1 December 2008

UK's NICE asked to develop new clinical health guidance for DoH

18 February 2008

FDA OKs Ixempra for breast cancer

22 October 2007

Showing 1-8 of 8 articles

Go to beginningPrevious
  • 1
NextGo to end